Moderna receives fda approval for emergency use authorization of 2nd booster dose of its covid-19 vaccine, mrna-1273

50 Μg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age cambridge, ma / accesswire / march 29, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, announced today that it has received approval from the u.s. food and drug administration (fda) for its amendment to the emergency use authorization (eua) to allow for a second booster dose of its covid-19 vaccine (mrna-1273) at the 50 Μg dose level in adults 50 years of age and older who have received an initial booster of any of the authorized or approved covid-19 vaccines and adults 18 years of age and older with certain kinds of immunocompromise. "the fda's endorsement of a second booster dose will allow millions of americans to build and maintain protection against sars-cov-2," said stÉphane bancel, chief executive officer of moderna.
MRNA Ratings Summary
MRNA Quant Ranking